| Trial ID: | L0980 |
| Source ID: | NCT00470171
|
| Associated Drug: |
Ursodeoxycholic acid
|
| Title: |
Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis
|
| Acronym: |
URSONASH
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Serum Levels of ALAT Transaminases;Serum Markers for Fibrosis and Hepatic Inflammation
|
| Interventions: |
Drug: Ursodesoxycholic acid
|
| Outcome Measures: |
A positive response is defined as a significantly larger decrease in average ALAT levels between the time of inclusion in the study and the end of the treatment for the ursodesoxycholic acid group as compared to the placebo group.nan
|
| Sponsor/Collaborators: |
Axcan Pharma
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Phase 2
|
| Enrollment: |
98
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
| Start Date: |
04/05/2007
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
19 February 2015
|
| Locations: |
France
|
| URL: |
http://clinicaltrials.gov/show/NCT00470171
|
